Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile
AHT-102（一种CLDN18.2 × CD3双特异性抗体）的临床前评价：药代动力学、抗肿瘤疗效、组织分布和安全性概况
期刊:Drugs in Research & Development
影响因子:2.1
doi:10.1007/s40268-026-00535-y
Chu, Huilun; Xu, Guili; Liu, Yunlong; Qian, Niliang; Li, Yanchuan; Liu, Yujie; Pan, Xiujie; Gao, Xin; Ou, Lun; Lv, Junping; Song, Haifeng
